Quotient expands operations with early phase manufacturing site

By Maggie Lynch

- Last updated on GMT

(Image: Getty/Jackkapan)
(Image: Getty/Jackkapan)

Related tags Drug development Drug development process operations Manufacturing formulation Clinical trial facility

Quotient Sciences, a drug development services organization, will expand its operations with a new early phase formulation development and clinical trial manufacturing facility.

Quotient Sciences has made a $15m investment into creating this new site, in an aim to expand its manufacturing operations in the US.

The new 45,000-square-foot facility, which will be a center of excellence for early-phase formulation development and clinical trial manufacturing, will be located near Philadelphia, PA.

The site will focus on the development of small molecule oral drugs, and support development programs from preclinical to clinical proof-of-concept. It also will allow for scale-up to late-phase manufacturing. Commercial product supply will continue at Quotient’s other Pennsylvania facility while the new facility is being built.

According to a statement made by Mark Egerton, CEO of Quotient, the new facility is designed to optimize the company’s ability to work with highly potent and poorly soluble molecules, which are currently a large part of the industry’s pipeline.

Quotient’s capacity to provide its Translational Pharmaceutics program to US customers will also be expanded by this new facility. The platform integrates formulation development, manufacturing, and clinical research.

The new facility is designed to handle both potent and non-potent products with six high-potency good manufacturing practice (GMP) suites.

The company plans to expand even more and will announce further expansion in the coming months.

Last year at the 2017 Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists (AAPS), Quotient announced its rebranding from Quotient Clinical to Quotient Sciences​. The company has 700 employees, five operating sites across the US and the UK.

Quotient was unable to provide further comment at this time. 

Related news

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers